Vista Klinik   Report issue

Academic/Hospital Phase 4
Founded: Binningen Switzerland (2009)

Organization Overview

First Clinical Trial
2010
NCT03393767
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Vista Klinik | Vista Klinik Binningen

Active Ingredients

Drugs in Phase 4 Trials (2)

aflibercept (zaltrap) (1 trial)

ranibizumab (lucentis) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Choroidal Neovascularization (Phase 4)

Macular Degeneration (Phase 4)

Neovascularization, Pathologic (Phase 4)

Wet Macular Degeneration (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 2